Table 2a.
Cortex phospholipid mass in SSADH deficient patient and control group
| nmol/g ww | mol % | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Patient | Mean (control) | SD | Patient | Mean (control) | SD | |
|
|
||||||
| EtnGpl | 28099 | 17735 | 1395* | 40.7% | 42% | 3.3% |
| PtdIns | 2393 | 1607 | 178* | 3.5% | 3.75% | 0.3% |
| PtdSer | 9308 | 4973 | 547* | 13.5% | 11.6% | 0.5%* |
| ChoGpl | 21319 | 14612 | 1619* | 30.9% | 34.1% | 2.3% |
| CerPCho | 7934 | 3838 | 355* | 11.5% | 9.0% | 0.7%* |
| Total | 69053 | 42765 | 2905* | |||
| n = 1 | n = 4 | |||||
Mass values are expressed as nmol phosphorus/gram wet weight tissue and represent mean±SD of control and patient values. Molar composition values are expressed as mol % of total phosphorus. n = 2–4.
*
indicates significance between patient and control group, 2 SD from control mean.